ホーム › 乳がん › コネチカット州 › Bridgeport
Bridgeport、CTにおける乳がんの臨床試験
Bridgeportとその周辺地域（約30マイル以内）の拠点で、乳がんに関する21件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Stony Brook University Medical Center, Stony Brook · 18マイル先
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
被験者募集中第3相
- Stony Brook University-Cancer Center ( Site 0034), Stony Brook · 18マイル先
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
被験者募集中第3相
- Research Site, Stony Brook · 18マイル先
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
被験者募集中第3相
- Smilow Cancer Hospital Care Center - Trumbull, Trumbull · 4マイル先
- Smilow Cancer Hospital Care Center - Fairfield, Fairfield · 5マイル先
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
被験者募集中
- Stony Brook Cancer Center, Stony Brook · 18マイル先
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
被験者募集中第1/2相
- Stony Brook University Hospital, Stony Brook · 18マイル先
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
被験者募集中第3相
- Stony Brook University Medical Center, Stony Brook · 18マイル先
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
被験者募集中第3相
- Stony Brook University Cancer Center, Stony Brook · 18マイル先
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
被験者募集中第3相
- New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C. (Port Jefferson Station2), Port Jefferson Station · 19マイル先
- New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C.(Port Jefferson Station1), Port Jefferson Station · 19マイル先
- New York Cancers & Blood Specialists, Port Jefferson Station · 19マイル先
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
被験者募集中第3相
- Hartford HealthCare - Saint Vincent's Medical Center, Bridgeport
- Smilow Cancer Hospital Care Center-Trumbull, Trumbull · 4マイル先
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield · 5マイル先
- 他1件
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
被験者募集中第2相
- Stony Brook Cancer Center, Stony Brook · 18マイル先
ATEMPT 2.0: Adjuvant T-DM1 vs TH
被験者募集中第2相
- Smilow Cancer Hospital Care center at Trumbull, Trumbull · 4マイル先
- Smilow Cancer Hospital Care center at Fairfield, Fairfield · 5マイル先
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
被験者募集中第1相
- New York Cancer and Blood Specialists, Port Jefferson Station · 19マイル先
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
被験者募集中第3相
- Stony Brook University Cancer Center, Stony Brook · 18マイル先
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
被験者募集中第3相
- Smilow Cancer Hospital - Fairfield, Fairfield · 5マイル先
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
被験者募集中第3相
- Smilow Cancer Hospital Care Center-Trumbull, Trumbull · 4マイル先
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield · 5マイル先
- Stony Brook University Medical Center, Stony Brook · 18マイル先
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
被験者募集中観察研究
- Stony Brook Medicine, Stony Brook · 18マイル先
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
被験者募集中早期第1相
- Stony Brook Breast Center, Stony Brook · 18マイル先
Definitive Radiation Therapy for Inoperable Breast Cancer
被験者募集中
- Stony Brook University Cancer Center, Stony Brook · 18マイル先
Definitive Radiation for High-Risk Spine Metastases
被験者募集中第2相
- Stony Brook University Hospital, Stony Brook · 18マイル先
CtDNA Based MRD Testing for NAC Monitoring in TNBC
被験者募集中観察研究
- Stony Brook University Cancer Center, Stony Brook · 18マイル先
他の都市における乳がんの試験
- New York City, NY136件の研究
- Houston, TX126件の研究
- Boston, MA112件の研究
- Nashville, TN81件の研究
- Los Angeles, CA73件の研究
- Edison, NJ68件の研究
- St. Louis, MO64件の研究
- Queens, NY64件の研究
- Durham, NC64件の研究
- Chicago, IL59件の研究
- Philadelphia, PA56件の研究
- Dallas, TX55件の研究
Bridgeportにおける他の研究
- 非小細胞肺癌14件の研究
- 肺がん13件の研究
- 急性骨髄性白血病12件の研究
- 心血管疾患9件の研究
- がん（全種類）8件の研究
- 頭頸部扁平上皮癌8件の研究
- 転移性癌7件の研究
- 心不全7件の研究
- 脳動脈瘤6件の研究
- 多発性骨髄腫6件の研究
- 前立腺がん6件の研究
- 卵巣がん5件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。